1
Tarran Jones
Neil I Goldstein, Nicholas A Giorgio, Steven Tarran Jones, Jose William Saldanha: Humanized anti-EGF receptor monoclonal antibody. ImClone Systems Incorporated, Kenyon & Kenyon, June 13, 2006: US07060808 (55 worldwide citation)

A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.


2
Zhu Zhenping: Novel tetravalent bispecific antibody. Imclone Systems Incorporated, Zhu Zhenping, DELUCIA Richard L, February 23, 2006: WO/2006/020258 (56 worldwide citation)

The invention is directed to novel tetravalent antibodies, which are preferably bi-specific. The tetravalent bispecific antibodies can be efficiently expressed in prokaryotic and eukaryotic cells, and are useful in therapeutic and diagnostic methods. The invention further describes administration of ...


3
Ludwig Dale L: Fully human antibodies directed against the human insulin-like growth factor-1 receptor. Imclone Systems Incorporated, Ludwig Dale L, SOMERVILLE Deborah A, February 24, 2005: WO/2005/016970 (43 worldwide citation)

This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic me ...


4
Zhenping Zhu: Human antibodies specific to KDR and uses thereof. ImClone Systems Incorporated, Lerner David Littenberg Krumholz & Mentlik, March 3, 2009: US07498414 (37 worldwide citation)

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, a ...


5
Patricia Rockwell, Neil I Goldstein: Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy. ImClone Systems Incorporated, Kenyon & Kenyon, November 2, 2004: US06811779 (31 worldwide citation)

The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal ...


6
Patricia Rockwell, Neil I Goldstein: Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors. ImClone Systems Incorporated, Hoffmann & Baron, November 24, 1998: US05840301 (29 worldwide citation)

Monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.


7
Sun Haijun, Shen Juqun, Tonra James R: Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof. Imclone Systems Incorporated, Sun Haijun, Shen Juqun, Tonra James R, SOMERVILLE Deborah A, April 28, 2005: WO/2005/037235 (29 worldwide citation)

The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention ...


8
David Segev: Chemical process for amplifying and detecting nucleic acid sequences. ImClone Systems Incorporated, Irving N Feit, Thomas C Gallagher, Eric J Sheets, December 8, 1998: US05846709 (27 worldwide citation)

The present invention is directed to a method of amplifying and detecting single or double stranded target nucleic acid molecules. Amplification of the target nucleic acid molecule is accomplished by using at least two chemically modified oligonucleotide probes per target nucleic acid molecule to fo ...


9
Piatnitski Evgueni, Kiselyov Alexander, Doody Jacqueline, Hadari Yaron, Ouyang Shawn, Chen Xiaoling: Anti-angiogenic compounds and their use in cancer treatment. Imclone Systems Incorporated, Piatnitski Evgueni, Kiselyov Alexander, Doody Jacqueline, Hadari Yaron, Ouyang Shawn, Chen Xiaoling, SOMERVILLE Deborah A, June 24, 2004: WO/2004/052280 (27 worldwide citation)

Compounds that inhibit angiogenesis and are useful in the treatment of angiogenic dependent diseases like cancer are disclosed as well as pharmaceutical compositions that contain such compounds, methods of treating angiogenic dependent diseases and conditions in mammals using such compounds and meth ...


10
Patricia Rockwell, Neil I Goldstein: Single chain antibodies specific to VEGF receptors. Imclone Systems Incorporated, Hoffmann & Baron, February 23, 1999: US05874542 (23 worldwide citation)

Monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.